Greenwich LifeSciences GLSI Insider Ownership

Updated Oct 10, 2026

In the last 12 months, insiders at Greenwich LifeSciences made open-market purchases of $586,328 (40.8K shares) and sold no shares on the open market.

• Among Greenwich LifeSciences' insiders, Snehal Patel (CEO and CFO) was the largest open-market buyer over the past 12 months, purchasing $586,328 of stock (40.8K shares), most recently on July 29, 2026.
• According to Business Quant data, insiders at Greenwich LifeSciences reported 9.08Mn shares in total in their latest Form 4 filings.
• Indirect holdings, through trusts, partnerships, family members and other entities, make up 29.89% (2.71Mn shares) of Greenwich LifeSciences' insider total, with the other 70.11% (6.36Mn shares) held directly.
• The insider holdings in Greenwich LifeSciences belong to 4 insiders who have reported on Form 4 within the past two years.
• GLSI's largest insider holders by reported holdings are Snehal Patel (CEO and CFO, 8.32Mn shares), Kenneth Hallock (Director, 397.3K shares) and Jaye Thompson (VP Clinical Reg Affairs, 264.15K shares).
• Of the shares held by GLSI insiders, 91.72% belong to Snehal Patel.
• Institutions owned 11.49% of GLSI shares as of Q2 2026; insiders' latest Form 4 filings account for about 61.83%, leaving roughly 26.68% with other investors, including the public.
• In the past year, one insider of Greenwich LifeSciences submitted 12 Form 4 filings reporting trades, awards or other transactions.
• These insider figures for Greenwich LifeSciences are based on Form 4 filings through July 30, 2026.